Evolving enzyme technology for pharmaceutical applications: case studies.
The case studies focus on two types of enzyme applications for pharmaceutical development. Demethylmacrocin O-methyltransferase, macrocin O-methyltransferase (both putatively rate-limiting) and tylosin reductase were purified from Streptomyces fradiae, characterized and the genes manipulated for increasing tylosin biosynthesis in S. fradiae. The rate-limiting enzyme, deacetoxycephalosporin C (DAOC) synthase/hydroxylase (expandase/ hydroxylase), was purified from Cephalosporium acremonium, its gene over-expressed, and cephalosporin C biosynthesis improved in C. acremonium. Also, heterologous expression of penicillin N epimerase and DAOC synthase (expandase) genes of Streptomyces clavuligerus in Penicillium chrysogenum permitted DAOC production in the fungal strain. Second, serine hydroxymethyltransferase of Escherichia coli and phthalyl amidase of Xanthobacter agilis were employed in chemo-enzymatic synthesis of carbacephem. Similarly, echinocandin B deacylase of Actinoplanes utahensis was used in the second-type synthesis of the ECB antifungal agent.
Yeh
W K
WK
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
D000900:Anti-Bacterial Agents / Q000096:biosynthesis*; D002511:Cephalosporins / Q000096:biosynthesis; D015645:Tylosin / Q000096:biosynthesis
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C026739:carbacephems; C025163:cephalosporin C; D015645:Tylosin